by Raynovich Rod | Oct 10, 2019 | Biopharmaceuticals
Update-2 10/13…Biotech IPOs Remain Weak-Recent rally was weak for small cap biotechs Vir Biotechnology (VIR): A clinical stage immunology and infectious disease Company focused on new therapies for hepatitis (HBV), Influenza A, HIV and TB went public on Friday....
by Raynovich Rod | Aug 19, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update -3 Bearish trends in biopharma continue with both the IBB and XBI down with 30 min of trading to go. We will do a review of the healthcare sector later this week continuing the theme after the AACC of the need for diversification within healthcare e.g. medtech,...
by Raynovich Rod | Jul 11, 2019 | Biopharmaceuticals
Update-1 11a EDT, Large cap drugs and biotechs resume slide on drug pricing “reform” from Trump threats. IBB down 1.37%, XPH in downtrend tp $38.41. Laggards holding BIB, GILD. Winners losing MRK, RHHBY. LLY and PFE hit hard. Gene therapy green: BOLD,SGMO....
by Raynovich Rod | Jun 17, 2019 | Biopharmaceuticals
Update-3. Red screen day, post after close, macro intervening again. BMY/CELG delayed on Otezla divestiture. Update -2 …Week Ending 6/21-Biotech stocks up for the week but momentum easing. XBI up 1.2% to $87.26, off Wednesday highs. IBB up .2.2% to $109.45 QQQ...
by Raynovich Rod | Jun 10, 2019 | Biopharmaceuticals, Macro
Update-3 6/17 11:30 a EDT Pfizer (PFE) $11B Buyout of Array Pharmaceuticals (ARRY) Sparks Rally in biotech. As usual M&A brings buyers into biotech. ARRY up 56% on Pfizer $11B buyout. XBI up 3.68% to $84.46. Green screen in mid-caps, gene therapy. ==========...
by Raynovich Rod | Apr 30, 2019 | Biopharmaceuticals
Biopharma Wrap-Up: Sideways to Neutral in Active Trading for Quarter Biopharma stocks ended the quarter in a snooze as investors took a wait and see attitude as earnings roll-out for large caps. The IBB was off 0.83% today to $106.42 and up 9% QTD. The XBI is still up...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 10, 2019 | Biopharmaceuticals
Biotech Stocks Hold Despite Last Thursday’s Sell-Off All in the Technicals For Now, Large Caps Look Steady Biotech ETFs lost momentum last week but held near term support near the 20 Day moving average. Now that most companies have reported we should not expect...
by Raynovich Rod | Jan 24, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update ….Jan 30 2:45p EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB...
by Raynovich Rod | Jan 8, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from BIO 2016. There...
